Brief: Axcella Announces Initiation Of Emmpower℠ Phase 2 Clinical Trial Of Axa1665
30/06/2021 12:29
June 30 (Reuters) - Axcella Health Inc AXLA.O :
* AXCELLA ANNOUNCES INITIATION OF EMMPOWER℠ PHASE 2 CLINICAL
TRIAL
OF AXA1665
* AXCELLA ANNOUNCES INITIATION OF EMMPOWER℠ PHASE 2 CLINICAL
TRIAL
OF AXA1665
Source text for Eikon: ID:nBw7mJcnba
Further company coverage: AXLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axcella Health
See all newsAxcella Health Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Axcella Health Inc- On Oct 4, Co Received Notice From Nasdaq That Co Had Regained Compliance With Nasdaq
Brief: Axcella Announces Reverse Stock Split Effective September 19, 2023
U.S. STOCKS ON THE MOVE-PDD Holdings, Catalent, Best Buy
Brief: Axcella Granted Patent For Long Covid Fatigue Treatment